Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 2 min ago
Peer-reviewedCC BY 4.0Frontiers in Immunology

Immunomodulatory and targeted therapies for metastatic colorectal cancer

  • Kuiliang Gao1
  • Qianqian Lv2
  • Lidan Zhao2
  • Zhen Wang1
  1. 1Department of Traditional Chinese Medicine, Qingdao Hospital of University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital)
  2. 2Emergency Department, Qingdao Hospital of University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital)
Open at sourceDOICite

Abstract

Metastatic colorectal cancer (mCRC) remains a major cause of cancer-related morbidity and mortality worldwide. Its systemic treatment has evolved from conventional cytotoxic chemotherapy toward biomarker-driven targeted therapy and immunotherapy. Advances in molecular profiling have refined patient selection for anti-EGFR and anti-VEGF therapies and have enabled the development of treatments directed against BRAF V600E, KRAS G12C, HER2 amplification, and other actionable alterations. In parallel, immune checkpoint inhibitors have transformed the management of microsatellite instability-high/mismatch repair-deficient mCRC, whereas microsatellite-stable disease remains largely resistant to immunotherapy and continues to require rational combination strategies. Despite these advances, primary and acquired resistance, dynamic clonal evolution, and the immunosuppressive tumor microenvironment remain major barriers to durable disease control. Circulating tumor DNA and multidimensional molecular profiling are increasingly being explored to monitor treatment response, identify emerging resistance, and guide sequential therapy. This review summarizes recent advances in targeted therapy and immunotherapy for mCRC and discusses priorities for developing adaptive, biomarker-driven treatment strategies.

Related

  1. Editorial: Targeted therapies in gastric cancer: molecular signatures and immune microenvironment insights
    Alessandro Mangogna, Laura Mariuzzi, Giuseppe Aprile +2
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textImmunologyGeneral medicineCrossrefDOAJ
  2. BUB signaling in cancer and molecular insights into targeted therapies
    Bhavika Baweja, Chainsee Saini, Prerna Vats +5
    Communications BiologyPeer-reviewedCC BY 4.0Full textCell biologyCrossref
  3. IDO1 methylation by EZH2 confers resistance to its targeted therapy in colorectal cancer through tryptophan-kynurenine metabolic rewiring
    Yuanjun Tang, Zhanya Huang, Yiting Jia +13
    Cell ReportsPeer-reviewedCC BY-NC-ND 4.0Full textGeneral biologyCrossrefDOAJ
  4. Targeting Ion Channel Dysregulation in Colorectal Cancer: Identification of Clofilium as a Potent Inhibitor of Tumor Growth and Metastatic Potential
    Juanita Mathews, Sydney A. Palmer, Sammy Hansali +7
    OSF PreprintsPreprintCC BY 4.0Full textGeneral biologyPhysiologyOSF
  5. Interpretable Multiomics Machine Learning Identifies GSDMB-Associated Epigenetic Repression and Reduced Immune Activity in Metastatic Colorectal Cancer
    M. d. S. Costa, H. I. Marcelo, G. A. Kafouri +1
    bioRxivPreprintCC BYFull textBioinformatics & computational biologybioRxiv

Cite

BibTeXRIS
BibTeX
@article{gao2026immunomodulatory,
  title = {{Immunomodulatory and targeted therapies for metastatic colorectal cancer}},
  author = {Kuiliang Gao and Qianqian Lv and Lidan Zhao and Zhen Wang},
  journal = {Frontiers in Immunology},
  year = {2026},
  month = nov,
  doi = {10.3389/fimmu.2026.1975205},
  url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1975205/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Immunomodulatory and targeted therapies for metastatic colorectal cancer
AU  - Kuiliang Gao
AU  - Qianqian Lv
AU  - Lidan Zhao
AU  - Zhen Wang
PY  - 2026
DA  - 2026/11/03
JO  - Frontiers in Immunology
DO  - 10.3389/fimmu.2026.1975205
UR  - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1975205/full
AB  - Metastatic colorectal cancer (mCRC) remains a major cause of cancer-related morbidity and mortality worldwide. Its systemic treatment has evolved from conventional cytotoxic chemotherapy toward biomarker-driven targeted therapy and immunotherapy. Advances in molecular profiling have refined patient selection for anti-EGFR and anti-VEGF therapies and have enabled the development of treatments directed against BRAF V600E, KRAS G12C, HER2 amplification, and other actionable alterations. In parallel, immune checkpoint inhibitors have transformed the management of microsatellite instability-high/mismatch repair-deficient mCRC, whereas microsatellite-stable disease remains largely resistant to immunotherapy and continues to require rational combination strategies. Despite these advances, primary and acquired resistance, dynamic clonal evolution, and the immunosuppressive tumor microenvironment remain major barriers to durable disease control. Circulating tumor DNA and multidimensional molecular profiling are increasingly being explored to monitor treatment response, identify emerging resistance, and guide sequential therapy. This review summarizes recent advances in targeted therapy and immunotherapy for mCRC and discusses priorities for developing adaptive, biomarker-driven treatment strategies.
SN  - 1664-3224
ER  -